TRPTI Metabolic and GLP-1 Pharmacodynamic Study

StatusNot Yet Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
RDC Clinical Pty Ltd
19 trials monitored
See 2 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
The goal of this clinical trial is to assess whether TRPTI™ supplementation affects GLP-1 and related metabolic markers in generally healthy adults who are overweight or obese (BMI 25.0-34.9 kg/m², aged 30 years and older). Researchers will compare TRPTI™ 150 mg to a matching placebo capsule to see if TRPTI™ produces a meaningful difference in GLP-1 response and associated metabolic and appetite-related markers over 8 hours. Participants will attend two 9-hour clinic visits (crossover design, with a minimum 6-day washout between visits).
Trial Details
NCT Number NCT07850466
Lead Sponsor RDC Clinical Pty Ltd
Collaborators: Gencor Pacific Limited, Hong Kong
Conditions
(from sponsor)		 Overweight , Obesity
Related terms Obesity, Overweight
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov